This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Colorado’s Prescription Drug Affordability Review Board (PDAB) isn’t waiting for the Inflation Reduction Act (IRA) to lower prices on certain drugs starting in 2026. After the review board unanimously agreed that Stelara is "unaffordable," the drug could be subject to an upper payment limit in the state.
billion by 2026. Jazz Pharmaceuticals has introduced a new prescription medication for patients with sleep apnea/narcolepsy that “helped adults get up to 9 hours of improved wakefulness in clinical studies at 12 weeks” and they’re using a flying pig on their DTC. This DTC is an embaressment.
Our healthcare system makes too much money for insurers, PBM’s and pharma companies to change. By 2026, national health expenditures will reach $5.7 It’s simple: people trust each other more than pharma companies who they view with a high degree of skepticism. It’s a good read but ignores a simple fact.
The bolt-on deal comes shortly after Ipsen announced plans to sell its consumer health business for around €350 million, leaving it as a pure-play prescriptionpharma operating in the cancer, rare diseases and neuroscience categories. Ipsen’s CVR offer includes $0.30
This product would be a more potent prescription version than the OTCs, Casberg notes. The product, manufactured by ARS Pharma and Neurelis Pharma, would be the first needle-free epinephrine alternative to autoinjectors, such as the EpiPen. Starting in 2026, the provision will affect 10 Part D drugs.
This is especially significant for manufacturers of high-cost specialty drugs, who will now face a recurring additional 20% charge on virtually every prescription fill. pharma sales in 2020) and the size of 340B discounts (25-50%), companies may see significantly reduced revenues for important products. The 340B battle will rage on.
As a mission-driven company and digital healthcare leader, GoodRx has helped patients obtain an estimated 80 million prescriptions they otherwise may not have been able to afford. Figure 1: Share of net spending for specialty and traditional prescription medications. The Uses—and Costs—of Specialty Treatments Keep Rising A U.S.
While global health spending per capita was about US$1,100 in 2018, this is forecast to rise to US$1,700 by 2026, outpacing GDP growth over the same period. In pharma, for instance, the global top 20 companies accounted for only about 35% market share in 1981, yet this figure had jumped to 65% by 2022.
The initial list, which takes effect in 2026, has the potential to roil formularies since it includes a mix of high-volume, preferred brands and a group of high-cost specialty drugs for autoimmune conditions (psoriasis) and cancer. In both cases, a shift in formulary placement could lower prescription volumes and reduce member utilization.
FDA director Robert Califf gave his prognosis for the pharma industry at this year’s JP Morgan Healthcare Conference in San Francisco over January 9–12. That leaves three years for pharma companies to prepare. Nonetheless, Cailiff expressed optimism about US innovation and adaptability in the face of these changes.
The prescription medicine market has recovered from the wild swings of the early pandemic with renewed growth. COVID vaccines and treatments have created a substantial market over and above the existing Rx market- IQVIA estimates that the cumulative value of COVID vaccines could be between $185 and 295bn to 2026.
Pharma may have to navigate a difficult path through relatively slow-to-fall inflation in regions outside the US. The legislation contains several provisions to lower prescription drug costs, including allowing Medicare to negotiate the cost of selected medicines. The entire pharma industry will be affected by the fallout.
Pharma may have to navigate a difficult path through relatively slow-to-fall inflation in regions outside the US. The legislation contains several provisions to lower prescription drug costs, including allowing Medicare to negotiate the cost of selected medicines. The entire pharma industry will be affected by the fallout.
Moreover, the initial set of negotiated prices represents the first step of a process that eventually will reshape the pricing and reimbursement landscape for prescription drugs under Medicare as CMS gradually replaces private payers as the chief negotiating partner for some of the drug industry’s largest-selling treatments.
Nationwide, prescription drug spending last year is estimated to be $328 billion among all payers, including private insurance, Medicare Part D, and patients’ out-of-pocket expenses. Still, the pharma industry is fighting hard to keep it off the table. Nearly 9 in 10 older adults take prescription medication.
Since the government first created a Part D benefit with the Medicare Modernization Act of 2003 (MMA) , Democrats have agitated for greater governmental input into the cost of prescription drugs for Medicare beneficiaries. Such a change would sharply increase the number of people covered under this program.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content